INmune Bio Advances with CORDStrom™ Patent Milestone
Significant Patent Advancements for INmune Bio
INmune Bio Inc. (NASDAQ: INMB), a pioneering biotechnology company, has reached a remarkable milestone with its CORDStrom™ platform technology. This advancement takes the company one step closer to delivering innovative therapies that address inflammation and immunology through the innate immune system.
CORDStrom™: A Breakthrough in Cell Therapy
Recently, the United States Patent and Trademark Office (USPTO) issued a favorable written opinion on all claims in INmune Bio's international patent application, PCT/US25/17028. This application details a novel therapeutic composition comprising pooled, culture-expanded human umbilical cord-derived mesenchymal stromal cells (hucMSCs). The opinion confirmed the novelty, inventive steps, and industrial applicability of all claims, which establish vital criteria for patentability on an international scale.
The CORDStrom™ platform is not just another product; it represents a transformative approach to cell therapy by providing consistent and scalable therapeutic solutions designed for injections or infusions. This enhances the potential to treat a wide array of inflammatory and degenerative conditions effectively.
Expert Insights on CORDStrom™
Joshua Schoonover, the General Counsel of INmune Bio, expressed his enthusiasm regarding the favorable examination results. He noted that CORDStrom is a first-of-its-kind product with batch-to-batch consistency, amplifying therapeutic effectiveness across various diseases. He emphasized that once granted, the patent application will cement intellectual property exclusivity through at least 2045, potentially extending past this date through additional patent adjustments.
Accelerating Patent Prosecution
To speed up the process, INmune Bio plans to employ the Patent Prosecution Highway (PPH). This program facilitates an expedited examination based on favorable outcomes from international patent offices, enhancing efficiency and reducing timeframes associated with patent approval.
Clinical Advancements and Future Potential
Complementing this patent news, initial data from a recent randomized Phase 2 trial indicate that CORDStrom™ effectively reduced symptoms such as pain and itching, with promising signs of improved overall skin integrity and reduced disease activity. The firm views these developments as crucial strides towards realizing the full therapeutic and commercial potential of the CORDStrom platform.
Understanding CORDStrom™
CORDStrom™ is a cutting-edge, patent-pending cellular medicine marbled from aseptic, allogeneic pooled hucMSCs, designed for ease of injection and infusion. INmune Bio employs exclusive methods of screening, pooling, and expanding these cells, ultimately creating robust, ready-to-use medicines aimed at treating complex inflammatory diseases. The goal is to manufacture products that ensure high-quality, consistent results regardless of donor variability.
Initially developed at INKmune® manufacturing facilities, CORDStrom™ is the result of significant research and efforts to position it as a first systemic therapy for challenging conditions like recessive dystrophic epidermolysis bullosa (RDEB). The CORDStrom platform is versatile, enabling the development of indication-specific products tailored to optimize the therapeutic properties for various disease states.
About INmune Bio Inc.
INmune Bio Inc. is publicly traded on NASDAQ (NASDAQ: INMB) and focuses on innovating treatments that leverage the innate immune system to fight various diseases. The company maintains three main product platforms, including the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that targets soluble TNF—critical in innate immune dysfunction. Their product candidates are currently under investigation to address conditions like Alzheimer’s disease, treatment-resistant depression, and more.
Moreover, the Natural Killer Cell Priming Platform includes the well-known INKmune®, which seeks to activate a patient’s NK cells to combat minimal residual disease in cancer patients, currently featuring a Phase II trial in metastatic castration-resistant prostate cancer. The advancements seen in CORDStrom™ further strengthen INmune Bio's commitment to transforming cell therapy.
Frequently Asked Questions
What is CORDStrom™?
CORDStrom™ is an innovative cell medicine utilizing pooled, culture-expanded human umbilical cord-derived mesenchymal stromal cells, aimed at treating complex inflammatory diseases.
What recent news did INmune Bio announce?
INmune Bio received a favorable patent opinion for the CORDStrom™ platform, indicating all claims meet patentability requirements.
What are the potential applications of CORDStrom™?
CORDStrom™ has the potential to treat various inflammatory and degenerative conditions and shows promise in ongoing clinical trials.
Who is the CEO of INmune Bio?
The current General Counsel, Joshua Schoonover, has been vocal about the advancements in the company's product lines, showcasing its forward momentum.
How is INmune Bio addressing patient needs?
INmune Bio focuses on developing scalable, consistent, and effective treatments that provide real solutions for patients suffering from severe inflammatory diseases.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
